


# **AMENDMENTS TO THE CLAIMS:**

Please cancel claims 1-31, without prejudice or disclaimer, and add new claims 32-61. This listing of claims below will replace all prior versions and listings of claims in the application.


32. (New): A compound of formula (I):




wherein:

- R<sub>1</sub> represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group;
- R<sub>2</sub> represents a group of formula i) or ii)

i)



ii)



wherein:

- R<sub>3</sub> represents a group chosen from phenyl, 2-furyl, 3-furyl, 2-thienyl and 3-thienyl;

- R<sub>4</sub> represents a group chosen from optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, cycloalkyl, cycloalkylmethyl, phenyl, benzyl, phenethyl, 2-furyl, 3-furyl, 2-thienyl and 3-thienyl; and

- R<sub>5</sub> represents a hydrogen atom or a hydroxy, methyl, or -CH<sub>2</sub>OH group; wherein the benzene rings in formula ii) and the cyclic groups represented by R<sub>3</sub> and R<sub>4</sub> are each independently optionally substituted by one, two or three, identical or different, substituents chosen from halogen, straight or branched, optionally substituted lower alkyl, hydroxy, straight or branched, optionally substituted lower alkoxy, nitro, cyano, -CO<sub>2</sub>R' and -NR'R'', wherein R' and R'' each independently represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group or R' and R'' together with the atom to which they are attached form a cyclic group;

- Q represents a single bond or a -CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-, -O-, -O-CH<sub>2</sub>-, -S-, -S-CH<sub>2</sub>- or -CH=CH- group; and


- p is 1 or 2 and the amide group is at positions 2, 3 or 4 of the azabicyclic ring; or pharmaceutically acceptable salt thereof, or a stereoisomer or a mixture thereof;

with the proviso that when p is 2, the amide moiety is in position 3 of the quinuclidine ring, R<sub>1</sub> is hydrogen and R<sub>3</sub> and R<sub>4</sub> are both unsubstituted phenyl, then

- when the compound is not a pharmaceutically acceptable salt or is a HCl salt, then R<sub>5</sub> cannot be one of hydrogen or hydroxy; and

- when the compound is a quaternary ammonium salt having a methyl group attached to the nitrogen atom of the quinuclidine ring, then R<sub>5</sub> cannot be hydroxy.

33. (New): The compound according to Claim 32, wherein the compound is a quaternary ammonium salt of formula (II)



wherein

- m is an integer ranging from 0 to 8;
- n is an integer ranging from 0 to 4;
- A represents a group chosen from -CH<sub>2</sub>-, -CH=CR'-, -CR'=CH-, -CR'R''-, -C(O)-, -O-, -S-, -S(O)-, -S(O)<sub>2</sub>- and -NR'-, wherein R' and R'' each independently represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group or R' and R'' together with the atom to which they are attached form a cyclic group;
- R<sub>6</sub> represents a hydrogen atom, or a group chosen from straight or branched, optionally substituted lower alkyl, hydroxy, straight or branched, optionally substituted lower alkoxy, cyano, nitro, -CH=CR'R'', -C(O)OR', -OC(O)R', -SC(O)R', -C(O)NR'R'', -NR'C(O)OR'', -NR'C(O)NR'', cycloalkyl, phenyl, naphthanelyl, 5,6,7,8-tetrahydronaphthanelyl, benzo[1,3]dioxolyl, heteroaryl and heterocyclyl; wherein R' and R'' each independently represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group or R' and R'' together with the atom to which they are attached form a cyclic group;

and wherein the cyclic groups represented by  $R_6$  are optionally substituted by one, two or three, identical or different, substituents chosen from halogen, hydroxy, straight or branched, optionally substituted lower alkyl, phenyl,  $-OR'$ ,  $-SR'$ ,  $-NR'R''$ ,  $-NHCOR'$ ,  $-CONR'R''$ ,  $-CN$ ,  $-NO_2$  and  $-COOR'$ ; wherein  $R'$  and  $R''$  each independently represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group or  $R'$  and  $R''$  together with the atom to which they are attached form a cyclic group; and

-  $X^-$  represents a pharmaceutically acceptable anion of a mono or polyvalent acid,

or a stereoisomer or mixture thereof;

with the proviso that when  $p$  is 2, the amide moiety is in position 3 of the quinuclidine ring,  $R_1$  is hydrogen,  $R_3$  and  $R_4$  are both unsubstituted phenyl and  $R_5$  is hydroxy, then in the compounds of formula (II) the sequence  $R_6 - (CH_2)_n - A - (CH_2)_m -$  cannot be a methyl group.

34. (New): The compound according to Claim 32, wherein  $R_1$  is hydrogen, methyl or ethyl.

35. (New): The compound according to claim 34, wherein  $R_1$  is hydrogen.

36. (New) The compound according to Claim 32, wherein  $R_2$  is a group of formula i), wherein  $R_3$  is a group, which is optionally substituted with at least one halogen atom, chosen from phenyl, 2-thienyl, 3-thienyl and 2-furyl.

37. (New): The compound according to Claim 36, wherein  $R_2$  is a group of formula i), and wherein  $R_3$  is a group, which is optionally substituted with at least one halogen atom, chosen from phenyl, 2-thienyl and 2-furyl.

38. (New): The compound according to Claim 37, wherein  $R_2$  is a group of formula i), wherein  $R_3$  represents a group chosen from phenyl and 2-thienyl.

39. (New): The compound according to Claim 32, wherein  $R_4$  represents a linear group chosen from ethyl, n-butyl, vinyl, allyl, 1-propenyl and 1-propynyl, or a group, which is optionally substituted with at least one substituent chosen from halogen atoms, methyl groups, and methoxy groups, chosen from cyclopentyl, cyclohexyl, phenyl, benzyl, phenethyl, 2-thienyl and 3-furyl.

40. (New): The compound according to Claim 39, wherein  $R_4$  represents a linear group chosen from ethyl, n-butyl, vinyl, allyl and 1-propynyl, or a group, which is optionally substituted with at least one substituent chosen from halogen atoms, methyl, and methoxy groups, chosen from cyclopentyl, phenyl, benzyl, phenethyl and 2-thienyl.

41. (New): The compound according to Claim 40, wherein  $R_4$  represents a group chosen from ethyl, n-butyl, vinyl, allyl, cyclopentyl, phenyl, benzyl, and 2-thienyl.

42. (New): The compound according to Claim 32, wherein  $R_2$  is a group of formula ii), wherein Q represents a single bond or an oxygen atom.

43. (New): The compound according to Claim 32, wherein R<sub>5</sub> is hydrogen or hydroxy.

44. (New): The compound according to Claim 32, wherein p is 2 and the amide group is at positions 3 or 4 of the azabicyclic ring.

45. (New): The compound according to Claim 44, wherein the amide group is at position 3 of the azabicyclic ring.

46. (New): The compound according to Claim 33, wherein,

- m is an integer ranging from 0 to 6;

- n is an integer ranging from 0 to 4;

- A represents a group chosen from -CH<sub>2</sub>-, -CH=CH-, -O-, -C(O)-, -NR'-, and -S-;

and

- R<sub>6</sub> is a hydrogen atom, a cyano group, a nitro group, a -C(O)OR' group, a -OC(O)R' group, a -SC(O)R' group, a -CH=CH<sub>2</sub> group, a -CH=CR'R'' group, a C(O)NR'R'' group, a straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl group, which is optionally substituted with at least one halogen atom, a straight C<sub>1</sub>-C<sub>4</sub> alkoxy group, which is optionally substituted with at least one substituent chosen from halogen atoms, hydroxy groups, and a cyclic group, which is optionally substituted with at least one substituent chosen from halogen atoms, groups of formula -C(O)NR'R'' and methyl, hydroxy, nitro and phenyl groups, wherein the cyclic group is chosen from cyclohexyl, phenyl, 5,6,7,8-tetrahydronaphthanelyl, 2-thienyl, 1-pyrrolidinyl, 1-pyrrolyl, benzo[1,3]dioxolyl, 2-benzothiazolyl, naphthalenyl and dioxolyl.

47. (New): The compound according to Claim 46, wherein,

- m is an integer ranging from 0 to 5;
- n is an integer ranging from 0 to 2;
- A represents a group chosen from  $-\text{CH}_2-$ ,  $-\text{CH}=\text{CH}-$ ,  $-\text{O}-$ ,  $-\text{C}(\text{O})-$ ,  $-\text{NR}'-$ , and  $-\text{S}-$ ; and
- $\text{R}_6$  is a hydrogen atom, a cyano group, a  $-\text{C}(\text{O})\text{OR}'$  group, a  $-\text{OC}(\text{O})\text{R}'$  group, a  $-\text{SC}(\text{O})\text{R}'$  group, a  $-\text{CH}=\text{CH}_2$  group, a  $-\text{C}(\text{O})\text{NR}'\text{R}''$  group, a straight or branched  $\text{C}_1$ - $\text{C}_4$  alkyl group, a trifluoromethyl, or a cyclic group chosen from cyclohexyl, 5,6,7,8-tetrahydronaphthanyl, 2-thienyl, 1-pyrrolyl, benzo[1,3]dioxolyl, 2-benzothiazolyl, naphthalenyl, dioxolyl and phenyl, wherein the cyclic group is optionally substituted with at least one substituent chosen from halogen atoms, groups of formula  $-\text{C}(\text{O})\text{NR}'\text{R}''$ , methyl, hydroxy and phenyl groups.

48. (New): The compound according to Claim 47, wherein,

- m is an integer ranging from 0 to 5;
- n is an integer ranging from 0 to 2;
- A represents a group chosen from  $-\text{CH}_2-$ ,  $-\text{CH}=\text{CH}-$ , and  $-\text{O}-$ ; and
- $\text{R}_6$  is chosen from hydrogen, straight  $\text{C}_1$ - $\text{C}_4$  alkyl group,  $-\text{CH}=\text{CH}_2$  group, cyclohexyl group, and a phenyl group, wherein the phenyl group is optionally substituted with one or two, identical or different, substituents chosen from methyl groups and hydroxy groups, 5,6,7,8-tetrahydronaphthanyl and 2-thienyl.

49. (New): The compound according to Claim 48, wherein the sequence  $R_6 - (CH_2)_n - A - (CH_2)_m -$  is chosen from methyl, 3-phenoxypropyl, 3-(3-hydroxyphenoxy)propyl, allyl, heptyl, 3-phenylpropyl, 3-phenylallyl, 2-phenoxyethyl, 2-benzyloxyethyl, cyclohexylmethyl, 3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl, 5-(2,6-dimethylphenoxy)pentyl, 3-thien-2-ylpropyl and 3-cyclohexylpropyl and  $X^-$  is bromide or trifluoroacetate.

50. (New): The compound according to Claim 32, wherein the compound is a single isomer.

51. (New): The compound according to Claim 32 chosen from:

- N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide;
- N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2-hydroxy-2,2-dithien-2-ylacetamide;
- N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-2-hydroxy-2,2-dithien-2-ylacetamide;
- N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2,2-dithien-2-ylacetamide;
- N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2-cyclopentyl-2-hydroxy-2-thien-2-ylacetamide;
- N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2-hydroxy-2-thien-2-ylpent-4-enamide;
- (2\*)-N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2-hydroxy-2-thien-2-ylbutanamide (diastereomer 1);
- (2\*)-N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2-hydroxy-2-thien-2-ylbutanamide (diastereomer 2);
- (2\*)-N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2-hydroxy-2-thien-2-ylbut-3-enamide (diastereomer 1);



- (2\*)-N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2-hydroxy-2-thien-2-ylbut-3-enamide  
(diastereomer 2);
- N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3-diphenylpropanamide;
- N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2-cyclopentyl-2-hydroxy-2-phenylacetamide;
- N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2-phenylhexanamide;
- N-(1-Azabicyclo[2.2.2]oct-3-yl)-9H-xanthene-9-carboxamide;
- N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-9H-xanthene-9-carboxamide;
- N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-9H-xanthene-9-carboxamide;
- N-(1-Azabicyclo[2.2.2]oct-3-yl)-9-hydroxy-9H-fluorene-9-carboxamide;
- N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-N-methyl-9H-xanthene-9-carboxamide;
- (2S)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-2-cyclopentyl-2-hydroxy-2-thien-2-ylacetamide;
- 3-(2-Hydroxy-2,2-dithien-2-ylacetyl-amino)-1-methyl-1-azoniabicyclo[2.2.2]octane  
bromide;
- 3-(2-Hydroxy-2,2-dithien-2-ylacetyl-amino)-1-(3-phenoxypropyl)-1-  
azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetyl-amino)-1-methyl-1-azoniabicyclo[2.2.2]octane  
trifluoroacetate;
- (3R)-1-Allyl-3-(2-hydroxy-2,2-dithien-2-ylacetyl-amino)-1-azoniabicyclo[2.2.2]octane  
trifluoroacetate;
- (3R)-1-Heptyl-3-(2-hydroxy-2,2-dithien-2-ylacetyl-amino)-1-azoniabicyclo[2.2.2]octane  
trifluoroacetate;


- (3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetyl amino)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetyl amino)-1-((E)-3-phenylallyl)-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetyl amino)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetyl amino)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetyl amino)-1-[3-(3-hydroxyphenoxy)propyl]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-1-(2-Benzyloxyethyl)-3-(2-hydroxy-2,2-dithien-2-ylacetyl amino)-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3R)-3-(2-Hydroxy-2,2-dithien-2-ylacetyl amino)-1-(3-thien-2-ylpropyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3S)-3-(2-Hydroxy-2,2-dithien-2-ylacetyl amino)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-(2,2-Dithien-2-ylacetyl amino)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide;
- 1-Methyl-3-[(9H-xanthen-9-ylcarbonyl)amino]-1-azoniabicyclo[2.2.2]octane bromide;
- 1-(3-Phenoxypropyl)-3-[(9H-xanthen-9-ylcarbonyl)amino]-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-1-(3-Phenoxypropyl)-3-[(9H-xanthen-9-ylcarbonyl)amino]-1-azoniabicyclo[2.2.2]octane bromide;

- (3S)-1-Allyl-3-[(9H-xanthen-9-ylcarbonyl)amino]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3S)-1-Heptyl-3-[(9H-xanthen-9-ylcarbonyl)amino]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3S)-1-Cyclohexylmethyl-3-[(9H-xanthen-9-ylcarbonyl)amino]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3S)-1-(3-Cyclohexylpropyl)-3-[(9H-xanthen-9-ylcarbonyl)amino]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3S)-1-(3-Phenoxypropyl)-3-[(9H-xanthen-9-ylcarbonyl)amino]-1-azoniabicyclo[2.2.2]octane bromide;
- (3S)-1-[3-(5,6,7,8-Tetrahydronaphthalen-2-yloxy)propyl]-3-[(9H-xanthen-9-ylcarbonyl)amino]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- (3S)-1-[5-(2,6-Dimethylphenoxy)pentyl]-3-[(9H-xanthen-9-ylcarbonyl)amino]-1-azoniabicyclo[2.2.2]octane trifluoroacetate;
- 3-[(9-Hydroxy-9H-fluoren-9-yl)carbonyl]amino}-1-methyl-1-azoniabicyclo[2.2.2]octane bromide;
- 3-[(9-Hydroxy-9H-fluoren-9-yl)carbonyl]amino}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-1-[3-(2-Carbamoylphenoxy)propyl]-3-[(9-Hydroxy-9H-fluoren-9-yl)carbonyl]amino}-1-azoniabicyclo[2.2.2]octane formate;
- (3R)-1-[4-(4-Fluorophenyl)-4-oxobutyl]-3-[(9-Hydroxy-9H-fluoren-9-yl)carbonyl]amino}-1-azoniabicyclo[2.2.2]octane formate;

- (3R)-3-[[[9-Hydroxy-9H-fluoren-9-yl]carbonyl]amino]-1-[3-(methylphenylamino)propyl]-1-azoniabicyclo[2.2.2]octane chloride;
- (3R)-3-[[[9-Hydroxy-9H-fluoren-9-yl]carbonyl]amino]-1-(3-phenylsulfanylpropyl)-1-azoniabicyclo[2.2.2]octane formate;
- (3R)-3-[Methyl-(9H-xanthen-9-ylcarbonyl)amino]-1-(3-pyrrol-1-ylpropyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-1-[3-(Biphenyl-4-yloxy)propyl]-3-[methyl-(9H-xanthene-9-carbonyl)amino]-1-azoniabicyclo[2.2.2]octane chloride;
- (3R)-3-(2-Fur-2-yl-2-hydroxypent-3-ynoylamino)-1-[3-(naphthalen-1-yloxy)propyl]-1-azoniabicyclo[2.2.2]octane chloride;
- (3R)-1-[3-(Benzo[1,3]dioxol-5-yloxy)propyl]-3-(2-fur-2-yl-2-hydroxypent-3-ynoylamino)-1-azonia-bicyclo[2.2.2]octane bromide;
- (3R)-1-[3-(Benzothiazol-2-yloxy)propyl]-3-(2-fur-2-yl-2-hydroxypent-3-ynoylamino)-1-azonia-bicyclo[2.2.2]octane chloride;
- (3R)-3-[[[2S)-2-Cyclopentyl-2-hydroxy-2-thien-2-ylacetyl]amino]-1-(2-hydroxyethyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-3-[[[2S)-2-Cyclopentyl-2-hydroxy-2-thien-2-ylacetyl]amino]-1-(2-ethoxyethyl)-1-azoniabicyclo[2.2.2]octane formate;
- (3R)-3-[[[2S)-2-Cyclopentyl-2-hydroxy-2-thien-2-ylacetyl]amino]-1-(4,4,4-trifluorobutyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-1-(4-Acetoxybutyl)-3-[2-(5-bromothien-2-yl)-2-(4-fluoro-3-methylphenyl)-2-hydroxyacetyl]amino]-1-azoniabicyclo[2.2.2]octane bromide;

- (3R)-3-[2-(5-Bromothien-2-yl)-2-(4-fluoro-3-methylphenyl)-2-hydroxyacetyl-amino]-1-(4-ethoxycarbonylbutyl)-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-1-(3-Acetylsulfanylpropyl)-3-[2-(5-bromothien-2-yl)-2-(4-fluoro-3-methylphenyl)-2-hydroxyacetyl-amino]-1-azoniabicyclo[2.2.2]octane formate;
- (3R)-1-(3-Cyanopropyl)-3-[2-fur-2-yl-2-hydroxy-4-(4-methoxyphenyl)butyrylamino]-1-azoniabicyclo[2.2.2]octane bromide;
- (3R)-1-(2-Carbamoylethyl)-3-[2-fur-2-yl-2-hydroxy-4-(4-methoxyphenyl)butyrylamino]-1-azoniabicyclo[2.2.2]octane formate; and
- (3R)-1-(2-[1,3]Dioxolan-2-yl-ethyl)-3-[2-fur-2-yl-2-hydroxy-4-(4-methoxyphenyl)butyrylamino]-1-azoniabicyclo[2.2.2]octane bromide.

52. (New): A process for producing a compound of Claim 32, wherein  $R_2$  is a group of formula i) and  $R_5$  is an hydroxy group, wherein the process comprises reacting a compound of formula (V)




(V)

with the corresponding organometallic derivative  $R_4$ -[Mg,Li].

53. (New): The compound of formula (V), chosen from

- N-1-azabicyclo[2.2.2]oct-3-yl-2-oxo-2-thien-2-ylacetamide;
- N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-2-oxo-2-thien-2-ylacetamide; and
- N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-2-oxo-2-thien-2-ylacetamide.


54. (New): A process for producing a compound of claim 33, wherein the process comprises reacting a compound of formula (I)




wherein:

- R<sub>1</sub> represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group;
- R<sub>2</sub> represents a group of formula i) or ii)

i)



ii)



wherein:

- R<sub>3</sub> represents a group chosen from phenyl, 2-furyl, 3-furyl, 2-thienyl and 3-thienyl;
  - R<sub>4</sub> represents a group chosen from optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, cycloalkyl, cycloalkylmethyl, phenyl, benzyl, phenethyl, 2-furyl, 3-furyl, 2-thienyl and 3-thienyl; and
  - R<sub>5</sub> represents a hydrogen atom or a hydroxy, methyl, or -CH<sub>2</sub>OH group;
- wherein the benzene rings in formula ii) and the cyclic groups represented by R<sub>3</sub> and R<sub>4</sub> are each independently optionally substituted by one, two or three, identical or different, substituents chosen from halogen, straight or branched, optionally substituted lower alkyl, hydroxy, straight or branched, optionally substituted lower alkoxy, nitro, cyano, -CO<sub>2</sub>R' and -NR'R'', wherein R' and R'' each independently represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group or R' and R'' together with the atom to which they are attached form a cyclic group;
- Q represents a single bond or a -CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-, -O-, -O-CH<sub>2</sub>-, -S-, -S-CH<sub>2</sub>- or -CH=CH- group; and
  - p is 1 or 2 and the amide group is at positions 2, 3 or 4 of the azabicyclic ring; or pharmaceutically acceptable salt thereof, or a stereoisomer or a mixture thereof;

with the proviso that when p is 2, the amide moiety is in position 3 of the quinuclidine ring, R<sub>1</sub> is hydrogen and R<sub>3</sub> and R<sub>4</sub> are both unsubstituted phenyl, then

- when the compound is not a pharmaceutically acceptable salt or is a HCl salt, then R<sub>5</sub> cannot be one of hydrogen or hydroxy; and

- when the compound is a quaternary ammonium salt having a methyl group attached to the nitrogen atom of the quinuclidine ring, then R<sub>5</sub> cannot be hydroxy,

with an alkylating agent of formula R<sub>6</sub>-(CH<sub>2</sub>)<sub>n</sub>-A-(CH<sub>2</sub>)<sub>m</sub>-W, wherein

- W represents a suitable leaving group.

55. (New): A pharmaceutical composition comprising at least one compound of according to Claim 32 in admixture with at least one pharmaceutically acceptable carrier or diluent.

56. (New): A compound of Claim 32, wherein the compound is effective for the treatment of a pathological condition or disease susceptible to amelioration by antagonism of M3 muscarinic receptors.

57. (New): A method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of M3 muscarinic receptors, comprising administering to the subject an effective amount of at least one compound of Claim 32.

58. (New): The method according to Claim 57 wherein the pathological condition is chosen from respiratory, urological, and gastrointestinal disease or disorder.



59. (New): A combination product comprising,

- (i) at least one first compound of Claim 32; and
- (ii) at least one second compound effective in the treatment of at least one pathological condition chosen from respiratory, urological and gastrointestinal disease or disorder wherein the at least one first compound and the at least one second compound are administered simultaneously, separately, or sequentially.

60. (New): A combination product comprising,

- (i) at least one first compound of Claim 32; and
- (ii) at least one second compound chosen from  $\beta_2$  agonist, steroid, an antiallergic drug, phosphodiesterase IV inhibitor and a leukotriene D4 (LTD4) antagonist, wherein the at least one first compound and the at least one second compound are administered simultaneously, separately, or sequentially in the treatment of a respiratory disease.